Financial News
All News about Genmab A/S ADR
![](https://mms.businesswire.com/media/20221211005057/en/1661419/5/Genmab_Logo_Color_RGB.jpg)
![](https://investorplace.com/wp-content/uploads/2018/05/biotechmsn2-compressed.jpg)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU4.jpg)
![](https://g.foolcdn.com/editorial/images/712054/male-scientist-looking-through-microscope.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/08/22/aapharma_16.png?width=1200&height=800&fit=crop)
HC Wainwright Is Bullish On This Multiple Myeloma Focused Stock
August 22, 2022
Via Benzinga
![](https://g.foolcdn.com/editorial/images/711609/gettyimages-1151223270.jpg)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU1.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_22263.jpeg?width=1200&height=800&fit=crop)
Stocks That Hit 52-Week Lows On Friday
November 25, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_22686.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/movers_image_21865.jpeg?width=1200&height=800&fit=crop)
![](https://mms.businesswire.com/media/20221121005063/en/1642918/5/Genmab_Logo_Color_RGB.jpg)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU1.jpg)
![](https://mms.businesswire.com/media/20221103005411/en/1623850/5/Genmab_Logo_Color_RGB.jpg)
![](https://mms.businesswire.com/media/20221028005026/en/1616677/5/Genmab_Logo_Color_RGB.jpg)
![](https://g.foolcdn.com/editorial/images/705675/football-quarterback-throwing-hail-mary-pass.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/options_image_2251.jpeg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU33.jpg)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU77.jpg)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU77.jpg)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU4.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/09/27/aapharma_12.png?width=1200&height=800&fit=crop)
Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment
September 27, 2022
Via Benzinga
![](https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU1.jpg)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU5.jpg)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU5.jpg)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU2.jpg)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU2.jpg)
![](https://cdn.benzinga.com/files/images/story/2022/analyst_ratings_image_25908.jpeg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2017/05/IRU2.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.